Rosai-Dorfman Disease Global Market Report 2026

Rosai-Dorfman disease is a rare, benign disorder characterized by an overproduction and accumulation of a specific type of immune cell called histiocytes, primarily within lymph nodes. It often presents with painless, massive swelling of the lymph nodes, especially in the neck, but can also affect other tissues and organs. Diagnosis typically involves biopsy and histopathological examination, and treatment varies from observation to surgery or immunosuppressive therapy, depending on severity and organ involvement.

The main types of rosai-dorfman disease are classic (nodal) rosai-dorfman disease and extranodal rosai-dorfman disease. Classic (nodal) rosai-dorfman disease primarily involves lymph nodes, especially in the neck, causing painless swelling, the most common and recognizable form. It is treated with different procedure types, such as diagnosis and treatment, and is distributed through several routes of administration, including oral, parenteral, sublingual, and nasal. It occurs in different ages, such as children and adults, and the key end-users include hospitals, diagnostics, cancer centers, and others.

Tariffs have impacted the rosai-dorfman disease market by increasing the cost of imported diagnostic equipment, reagents, and immunotherapy drugs. Segments such as molecular diagnostics and parenteral treatments are particularly affected, with regions like North America and Europe facing higher import costs due to tariff regulations. This has led to increased operational expenses for hospitals and diagnostics centers. On the positive side, tariffs encourage local manufacturing of diagnostic kits and therapeutic agents, fostering domestic innovation and reducing dependence on imports.

The rosai-dorfman disease market research report is one of a series of new reports from The Business Research Company that provides rosai-dorfman disease market statistics, including rosai-dorfman disease industry global market size, regional shares, competitors with a rosai-dorfman disease market share, detailed rosai-dorfman disease market segments, market trends and opportunities, and any further data you may need to thrive in the rosai-dorfman disease industry. This rosai-dorfman disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rosai-dorfman disease market size has grown strongly in recent years. It will grow from $0.54 billion in 2025 to $0.58 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to limited awareness of rosai-dorfman disease, lack of standardized diagnostic protocols, reliance on surgical interventions, low research funding for rare diseases, restricted access to advanced immunohistochemistry techniques.

The rosai-dorfman disease market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancements in molecular diagnostics, development of targeted immunosuppressive therapies, increasing rare disease registries, rising collaboration between hospitals and research centers, growing adoption of personalized treatment protocols. Major trends in the forecast period include increasing awareness and early diagnosis of rare diseases, growth in personalized and targeted immunotherapy, rising investments in rare disease research, expansion of hospital and cancer center capabilities, adoption of multidisciplinary treatment approaches.

The growing demand for targeted therapies is expected to propel the growth of the rosai-dorfman disease market going forward. Targeted therapies are precision drugs that attack specific genetic mutations or cellular mechanisms promoting tumor development, sparing healthy cells. The growing demand for targeted therapies is due to their ability to attack disease-causing cells while minimizing damage to healthy tissues, leading to improved treatment outcomes and reduced side effects compared to traditional therapies. Targeted therapies treat rosai-dorfman disease by blocking key pathways such as MAPK/ERK, which drive abnormal histiocyte growth, effectively controlling the disease with fewer side effects. These precision treatments target disease-specific mechanisms while sparing healthy tissues. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, there were 247 targeted gene therapies in Phase II in the third quarter of 2023, an increase of 5% compared to the second quarter. Therefore, the growing demand for targeted therapies is driving the growth of the Rosai-Dorfman disease market.

The rising immune-related complications are expected to propel the growth of the rosai-dorfman disease market going forward. Immune-related complications are harmful conditions resulting from an overactive or dysfunctional immune response, commonly linked to infections, autoimmune diseases, or immune-based treatments. The rise in immune-related complications is driven by increasing immunotherapy use, which can overactivate the immune system and cause inflammation or damage healthy tissues. Rosai-Dorfman disease is linked to immune system dysregulation, with rising immune-related complications from autoimmune conditions, infections, or immunotherapies contributing to its onset or worsening. This surge drives increasing diagnosis, research focus, and treatment development for the disease. For instance, in 2025, according to the Sjogren's Foundation, a US-based nonprofit organization, posted in 2025, the global burden of autoimmune diseases has risen substantially by about 19.1% annually up to 2025, indicating a rising trend in immune-mediated conditions overall. Therefore, the rising immune-related complications are driving the growth of the Rosai-Dorfman disease market.

Major companies operating in the rosai-dorfman disease market are focusing on advancements in diagnostic techniques such as digital molecular and genetic testing, which allows for detection of genetic mutations and infectious agents by analyzing deoxyribonucleic acid or ribonucleic acid and enables accurate diagnosis, risk assessment, and personalized treatment. Molecular and genetic testing is a type of laboratory analysis that examines an individual's deoxyribonucleic acid, ribonucleic acid, or proteins to identify genetic changes or infectious agents, which is used to diagnose diseases, assess genetic risks, and guide personalized treatment plans. For instance, in February 2025, F. Hoffmann-La Roche AG, a Switzerland-based company specializing in pharmaceuticals and diagnostics, launches Sequencing By Expansion (SBX) technology, a next-generation sequencing (NGS) technology set to revolutionize genomic analysis by enhancing speed, accuracy, and scalability. Additionally, it also offers ultra-rapid whole genome or targeted sequencing for fast, broad genomic profiling to catch rare mutations or structural variants in rosai-dorfman disease tissue samples.

Major companies operating in the rosai-dorfman disease market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche AG, Merck And Co. Inc., Bristol Myers Squibb Company, Novartis AG, Canon Inc., Siemens Healthineers, GE HealthCare, Viatris Inc., Teva Pharmaceutical Industries Ltd., Memorial Sloan Kettering Cancer Center, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Mayo Foundation for Medical Education and Research, Zydus Pharmaceuticals Inc., SternMed GmbH, LGM Pharma, Niksan Pharmaceutical, Herbert Irving Cancer Center

North America was the largest region in the rosai-dorfman disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rosai-dorfman disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rosai-dorfman disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rosai-dorfman disease market consists of revenues earned by entities by providing services such as diagnostic services, clinical services, therapeutic services, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The rosai-dorfman disease market consists of sales of immunohistochemistry (IHC) kits and reagents, molecular diagnostic kits, targeted therapy drugs, magnetic resonance imaging, and computed tomography scans. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rosai-Dorfman Disease Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses rosai-dorfman disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rosai-dorfman disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rosai-dorfman disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Classic (Nodal) Rosai-Dorfman Disease; Extranodal Rosai-Dorfman Disease
• 2) By Procedure Type: Diagnosis; Treatment
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Age: Children; Adults
• 5) By End-User: Hospitals; Diagnostics; Cancer Centers; Other End-Users
• Subsegments:
• 1) By Classic (Nodal) Rosai-Dorfman Disease: Cervical Lymph Node Involvement; Axillary Lymph Node Involvement; Inguinal Lymph Node Involvement; Mediastinal Lymph Node Involvement; Generalized Lymphadenopathy
• 2) By Extranodal Rosai-Dorfman Disease: Cutaneous Or Subcutaneous Rosai-Dorfman Disease; Central Nervous System (CNS) Rosai-Dorfman Disease; Orbital Or Ocular Rosai-Dorfman Disease; Bone And Skeletal Rosai-Dorfman Disease; Nasal Or Sinus Rosai-Dorfman Disease; Renal Rosai-Dorfman Disease; Pulmonary Rosai-Dorfman Disease; Hepatic Or Splenic Rosai-Dorfman Disease; Breast Rosai-Dorfman Disease
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; F. Hoffmann-La Roche AG; Merck And Co. Inc.; Bristol Myers Squibb Company; Novartis AG; Canon Inc.; Siemens Healthineers; GE HealthCare; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Memorial Sloan Kettering Cancer Center; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma; Mayo Foundation for Medical Education and Research; Zydus Pharmaceuticals Inc.; SternMed GmbH; LGM Pharma; Niksan Pharmaceutical; Herbert Irving Cancer Center
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.